⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149904 | 0.61 | — | — | |
| SCHEMBL7799601 | 0.61 | — | — | |
| SCHEMBL10654567 | 0.60 | — | — | |
| SCHEMBL14477095 | 0.60 | — | — | |
| SCHEMBL16024975 | 0.59 | — | — | |
| SCHEMBL24737339 | 0.58 | LMNA (0.42) | — | |
| SCHEMBL16703905 | 0.58 | — | — | |
| SCHEMBL16510448 | 0.56 | LMNA (0.32) | — | |
| SCHEMBL17547286 | 0.55 | — | — | |
| SCHEMBL8473841 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20100074863-A1 | ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090004140-A1 | 4-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009003009-A1 | SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20050043545-A1 | 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | US | disclosed |
| EP-1440070-A1 | 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037894-A1 | 4-(5-MEMBERED)-HETEROARYL ACYL PYRROLIDINE DERIVATIVES AS HCV INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |